UNICA IRIS Institutional Research Information System

CHESSA, LUCHINO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 219.412
NA - Nord America 13.437
AS - Asia 7.006
SA - Sud America 1.337
AF - Africa 236
OC - Oceania 38
Continente sconosciuto - Info sul continente non disponibili 7
Totale 241.473
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 214.168
US - Stati Uniti d'America 13.137
SG - Singapore 2.761
CN - Cina 2.156
NL - Olanda 1.175
BR - Brasile 1.007
SE - Svezia 865
UA - Ucraina 745
VN - Vietnam 681
DE - Germania 589
FI - Finlandia 518
GB - Regno Unito 503
FR - Francia 385
HK - Hong Kong 326
IN - India 183
CA - Canada 168
BD - Bangladesh 147
KR - Corea 139
AR - Argentina 116
AT - Austria 79
IQ - Iraq 75
MX - Messico 74
ZA - Sudafrica 71
RU - Federazione Russa 63
JP - Giappone 60
ID - Indonesia 59
TR - Turchia 58
PL - Polonia 48
CO - Colombia 47
MA - Marocco 47
EC - Ecuador 46
IE - Irlanda 44
PK - Pakistan 44
ES - Italia 41
AU - Australia 35
VE - Venezuela 35
CL - Cile 33
PH - Filippine 33
SA - Arabia Saudita 32
UZ - Uzbekistan 28
MY - Malesia 27
KE - Kenya 24
CZ - Repubblica Ceca 23
BE - Belgio 22
PY - Paraguay 21
EG - Egitto 20
IR - Iran 20
TN - Tunisia 19
AZ - Azerbaigian 17
IL - Israele 17
LT - Lituania 16
TW - Taiwan 16
JM - Giamaica 15
JO - Giordania 15
KZ - Kazakistan 14
CH - Svizzera 13
PE - Perù 12
RO - Romania 12
TH - Thailandia 12
UY - Uruguay 12
AE - Emirati Arabi Uniti 11
DK - Danimarca 11
DZ - Algeria 10
LB - Libano 10
PA - Panama 10
KG - Kirghizistan 9
OM - Oman 9
TT - Trinidad e Tobago 9
AO - Angola 8
MD - Moldavia 8
PT - Portogallo 8
RS - Serbia 8
AL - Albania 7
BG - Bulgaria 7
BO - Bolivia 7
LV - Lettonia 7
SY - Repubblica araba siriana 7
GR - Grecia 6
HR - Croazia 6
KW - Kuwait 6
BY - Bielorussia 5
CR - Costa Rica 5
HU - Ungheria 5
MK - Macedonia 5
NP - Nepal 5
BA - Bosnia-Erzegovina 4
BH - Bahrain 4
CG - Congo 4
DO - Repubblica Dominicana 4
ET - Etiopia 4
HN - Honduras 4
MU - Mauritius 4
NO - Norvegia 4
PS - Palestinian Territory 4
SI - Slovenia 4
UG - Uganda 4
AP - ???statistics.table.value.countryCode.AP??? 3
EU - Europa 3
GE - Georgia 3
GT - Guatemala 3
Totale 241.413
Salva come PNG Salva come JPEG
Città #
Cagliari 207.343
Uta 5.009
Singapore 1.293
Ashburn 1.165
Dallas 1.162
Amsterdam 1.096
Fairfield 915
San Jose 913
Woodbridge 783
Chandler 735
Boardman 674
Houston 606
Nyköping 520
Ann Arbor 408
Jacksonville 394
Beijing 384
Seattle 359
Helsinki 354
Wilmington 353
Cambridge 294
Los Angeles 293
Hong Kong 290
Council Bluffs 261
Santa Clara 214
Ho Chi Minh City 211
New York 209
Lauterbourg 203
Boston 202
Hefei 196
Dearborn 193
Munich 178
Rome 170
Shanghai 160
The Dalles 152
Nanjing 150
Hanoi 125
Seoul 123
Milan 122
Buffalo 118
São Paulo 102
San Diego 83
Dong Ket 78
Frankfurt am Main 76
Redwood City 73
Orem 65
Guangzhou 64
London 61
Mansfield 57
Toronto 54
Nanchang 52
Nuremberg 52
Chicago 48
Tianjin 48
Turku 48
Vienna 47
Redondo Beach 46
Tokyo 45
Jiaxing 40
Montreal 40
Changsha 39
Oxford 38
Shenyang 38
Hebei 37
Warsaw 37
Paris 36
Atlanta 35
Norwalk 35
Rio de Janeiro 33
Brooklyn 32
Chennai 32
Dublin 32
Johannesburg 32
Da Nang 30
Baghdad 29
Casablanca 29
Manchester 27
Washington 27
Sassari 26
Haiphong 24
Naples 24
Tashkent 24
Denver 23
Dhaka 23
Orange 23
Verona 23
Belo Horizonte 22
Mountain View 22
Nottingham 22
San Mateo 22
Birmingham 21
Mexico City 21
Nairobi 21
Düsseldorf 20
Santiago 20
Stockholm 20
Basingstoke 19
Jakarta 19
Quito 19
Brussels 18
Lappeenranta 18
Totale 230.601
Salva come PNG Salva come JPEG
Nome #
Comparing the responses of countries and National Health Systems to the COVID-19 pandemic: a critical analysis with a case-report series 20.836
Exploring the Role of Killer Cell Immunoglobulin-Like Receptors and Their HLA Class I Ligands in Autoimmune Hepatitis 4.572
Absence of activating killer immunoglobulin-like receptor genes combined with hepatitis C viral genotype is predictive of hepatocellular carcinoma 3.368
Gastrointestinal Coronavirus disease 2019: epidemiology, clinical features, pathogenesis, prevention, and management 3.300
Killer cell immunoglobulin-like receptors and their HLA class I ligands in autoimmune hepatitis: a possible pathogenetic role ? 3.144
HLA-G is highly expressed by plasma cells infiltrating hepatic tissue of patients affected by autoimmune hepatitis 3.141
Altered profile of salivary proteins in patients with Autoimmune Hepatitis 2.978
Bone mass preservation with high-dose cholecalciferol and dietary calcium in HIV patients following antiretroviral therapy. Is it possible? 2.937
Role of interferon lambda 4 and ALT levels in optimising treatment of HCV for patients with low-stage fibrosis 2.832
Impact of direct-acting antiviral drugs for chronic hepatitis C on mood: Preliminary results from a longitudinal study 2.749
Impact of natural killer (NK) cells receptors gene haplotypes on the development of hepatocarcinoma in cirrhotic patients 2.728
Hippocampal axis dysfunction evaluation by Rey-Osterrieth Complex figure test (RCFT) should be included in minimal hepatic encephalopathy (MHE) assessment 2.642
IMPACT OF KILLER-CELL IMMUNOGLOBULIN-LIKE RECEPTORS ON PROGRESSION OF HEPATOCELLULAR CARCINOMA 2.602
Combination of IFNL4 polymorphisms and ALT reduction at 4 week of treatment with PEG IFN and Ribavirin is a new selection tool to optimize antiviral treatment allocation in HCV patients with low stage fibrosis 2.552
Behavior of bone mass in long-term HAART patients 2.503
Association of chronic hepatitis C with recurrent brief depression 2.476
FATTORI IMPLICATI NELLA STORIA NATURALE DELL'INFEZIONE DA VIRUS DELTA:IL RUOLO DEGLI INTERFERONI 2.441
Role of natural killercells receptors on the development and progression of hepatocellularcarcinoma 2.419
Role of HLA-G in autmoimmune hepatitis 2.315
INFLUENZA DEI POLIMORFISMI DELL’INTERFERONE LAMBDA NELLA STORIA NATURALE DELLA INFEZIONE CRONICA DA HBV: COINCIDENZA O REALTÀ? 2.306
Entropy of human leukocyte antigen and killer-cell immunoglobulin-like receptor systems in immune-mediated disorders: A pilot study on multiple sclerosis 2.217
Dynamics of TT virus infection in a cohort of HCV-infected patients achieving sustained virologic responce after treatment with direct-acting antivirals 2.172
Safety and efficacy of direct-acting antivirals in transfusion-dependent thalassemic patients with chronic hepatitis C 2.171
Evaluation of mild cognitive dysfunction by Montreal Cognitive Assessment test in patients with chronic HCV infection treated with direct antiviral agents 2.027
Human Leukocyte Antigen Complex and Other Immunogenetic and Clinical Factors Influence Susceptibility or Protection to SARS-CoV-2 Infection and Severity of the Disease Course. The Sardinian Experience 2.025
A multivariate approach for the brain impairment in patients with liver cirrhosi 2.000
La neopterina uraria come marker di attività immunologica nelle malattie infiammatorie croniche dell’intestino 1.954
Efficacy and tolerability of treatment with the new direct acting antivirals (DAAs) in thalassemic patients with chronic Hepatitis 1.920
Is the Inversion in the Trend of the Lethality of the COVID-19 in the Two Hemispheres due to the Difference in Seasons and Weather? 1.917
Add-on peginterferon alfa-2a to nucleos(t)ide analogue therapy for Caucasian patients with hepatitis B 'e' antigen-negative chronic hepatitis B genotype D 1.826
Evaluation of mild cognitive dysfunction by Montreal Cognitive Assessment test in co-infected HIV-HCV patients treated with the new direct acting antivirals (DAAs) 1.770
Long-latency potential study in minimal hepatic hencephalopaty 1.751
null 1.742
Treatment of chronic hepatitis C in patients with glucose-6-phosphate dehydrogenase deficiency: is ribavirin harmful? 1.712
null 1.710
The climate in the European Union and the enlarged European Region is a determinant of the COVID-19 case fatality ratio 1.703
The Effect of Exposure to SARS-CoV-2 Vaccination and Infection on Humoral and Cellular Immunity in a Cohort of Patients with Immune-Mediated Diseases: A Pilot Study 1.698
null 1.666
SAFETY AND EFFICACY OF PEG-IFN alpha 2a AND RIBAVIRIN FOR TREATMENT OF HEPATITIS C IN SARDINIAN ADULT PATIENTS WITH THALASSEMIA MAJOR: A SINGLE CENTRE REAL LIFE EXPERIENCE 1.656
Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B 1.644
Multidimensional geriatric assessment in elderly HIV patients 1.628
Evolution of the viral quasispecies tracked by sequence analysis during interferon treatment of chronic hepatitis C. 1.613
null 1.610
Awareness, discussion and non-prescribed use of HIV pre-exposure prophylaxis among persons living with HIV/AIDS in Italy: a Nationwide, cross-sectional study among patients on antiretrovirals and their treating HIV physicians 1.551
The COVID-19 incidence in Italian regions correlates with low temperature, mobility and PM10 pollution but lethality only with low temperature 1.539
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 1.527
HepaDisk – A new quality of life questionnaire for HCV patients 1.521
EVALUATION OF MILD COGNITIVE DYSFUNCTION BY MONTREAL COGNITIVE ASSESSMENT TEST IN PATIENTS WITH CHRONIC HCV INFECTION 1.513
Orthotopic liver transplantation in neurological Wilson desease: case report 1.495
Natural killer-cell immunoglobulin-like receptors trigger differences in immune response to SARS-CoV-2 infection 1.452
Profiling the risk of hepatocellular carcinoma after long-term HCV eradication in patients with liver cirrhosis in the PITER cohort 1.435
null 1.424
Individualized long-term treatment of chronic hepatitis C with interferon alpha (IFN alpha)-2a. 1.421
Real-life use of elbasvir/grazoprevir in adults and elderly patients: a prospective evaluation of comedications used in the PITER cohort 1.383
Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV 1.367
Evaluation of antibody response to BNT162b2 mRNA COVID-19 vaccine in patients affected by immune-mediated inflammatory diseases up to 5 months after vaccination 1.355
Neutralizing Antibodies Responses against SARS-CoV-2 in a Sardinian Cohort Group Up to 9 Months after BNT162b2 Vaccination 1.332
Evolution of the HCV quasispecies and pattern of response to interferon therapy in patients with chronic hepatitis C 1.329
Management of primary biliary cholangitis in the pre-obeticholic acid era, and the rate of non-response to ursodeoxycholic acid (UDCA), in a large real-world cohort of PBC patients in Italy: The CLEO-AIGO database 1.327
Real-world data on the treatment of primary biliary cholangitis with obeticholic acid in Italy: the CLEO-AIGO OCA cohort. 1.310
Optimization of hepatitis C virus screening strategies by birth cohort in Italy 1.302
Rate of non-response to ursodeoxycholic acid in a large real-world cohort of primary biliary cholangitis patients in Italy 1.285
Can antiretroviral therapy modify the clinical course of HDV infection in HIV positive patients? 1.281
La quasispecie del virus dell’epatite C: implicazioni biologiche e cliniche 1.250
A Protective HLA Extended Haplotype Outweighs the Major COVID-19 Risk Factor Inherited From Neanderthals in the Sardinian Population 1.236
null 1.208
Forecasting liver disease burden 1.198
Predictive Factors for Liver Disease Progression Following the Direct Acting Antivirals Induced Sustained Virological Response: Data from the Italian Platform for the Study of Viral Hepatitis Therapies (PITER) Cohort 1.185
Evaluation of HIV Transmission Clusters among Natives and Foreigners Living in Italy 1.139
Decrease in Incidence Rate of Hospitalizations Due to AIDS-Defining Conditions but Not to Non-AIDS Conditions in PLWHIV on cART in 2008-2018 in Italy 1.132
Advanced liver disease outcomes after hepatitis C eradication by human immunodeficiency virus infection in PITER cohort 1.110
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis 1.109
Epidemiological and Economic Evaluations According to Daa Treatment Access in Italy Based on Real Life Piter Cohort Data 1.105
A review of the main genetic factors influencing the course of COVID-19 in Sardinia: the role of human leukocyte antigen-G 1.100
Forecasting liver disease burden based on a real life cohort of the linked to care patients in Italy. Does the ‘underwater portion of the iceberg’ matter to reach the WHO HCV eliminating goals in the high HCV prevalent countries? 1.089
Risultati preliminari di uno studio di fase II con Sorafenib in pazienti anziani affetti da epatocarcinoma 1.083
Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An Innovate study protocol 1.074
Previous functional social and behavioral rhythms affect resilience to COVID-19-related stress among old adults 1.071
Long term effectiveness of DAA therapy in patients with chronic HCV and Mixed Cryoglobulinemic Syndrome 1.063
Clinical characterization and economic impact evaluation of antiHCV DAA treatment failure:real life data from the Italian Platform for the Study of Viral Hepatitis Therapies (PITER) 1.049
Optimization of Hepatitis C Virus screening strategies by birth cohort in Italy 1.045
L'approccio basato sui casi per la diagnosi di malattie epatiche 1.029
Forecasting Hepatitis C liver disease burden based on real life data. Does the hidden iceberg matter to reach the World Health Organization elimination goals? 1.007
Distribution of IL28B polymorphism in a cohort of Italians and immigrants with HCV infection: association with viraemia, stage of fibrosis and response to treatment 994
Mixed cryoglobulinemia: an important but frequently unrecognized and underestimated HCV-related condition in the real life practice 992
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 989
Combined Salivary Proteome Profiling and Machine Learning Analysis Provides Insight into Molecular Signature for Autoimmune Liver Diseases Classification 978
Solid Organ Transplantation During COVID-19 Pandemic: An International Web-based Survey on Resources’ Allocation 957
Forecasting Hepatitis C liver disease burden on real life data. Does the hidden iceberg matter to reach the elimination goals? 948
L'Italia come modello per l'Europa e per il mondo nelle politiche sanitarie per il trattamento dell'epatite cronica da HCV Gruppo 940
STUDY OF VALIDATION OF ANGIOGENESIS POLYMORPHISMS IN HCC PATIENTS TREATEDWITH SORAFENIB. INNOVATE STUDY 939
Effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients: Results of the Italian cohort of a post-marketing observational study 938
Evaluation of Antibody Response to Heterologous Prime-Boost Vaccination with ChAdOx1 nCoV-19 and BNT162b2: An Observational Study 932
COVID-19 Vaccine Hesitancy among Italian Healthcare Workers: Latent Profiles and Their Relationships to Predictors and Outcome 909
Iron concentration and distribution in the newborn liver 908
Modeling cost-effectiveness and health gains of a “universal“ versus “prioritized“ hepatitis C virus treatment policy in a real-life cohort 903
HCV-related mixed cryoglobulinemia: Data from PITER, a nationwide Italian HCV cohort study 890
The prevalence of bright liver echo pattern in patients with chronic hepatitis C: correlation with steatosis and fibrosis 889
Covid-19 vaccines work but other factors play a relevant role: a data analysis on spread and mortality in 24 countries 881
Diagnostic and therapeutic approaches of mixed cryoglobulinemia in PITER (Piattaforma Italiana per lo studio della Terapia delle Epatiti viRali) cohort 879
Totale 183.270
Salva come PNG Salva come JPEG
Categoria #
all - tutte 330.752
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 330.752
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.807 0 0 0 0 0 0 0 0 0 0 0 1.807
2021/202213.215 1.217 1.135 703 1.000 958 985 865 724 1.097 996 1.535 2.000
2022/202319.438 2.076 2.643 2.596 1.408 1.692 1.926 893 1.655 1.133 1.086 1.435 895
2023/202422.027 1.023 1.137 1.230 1.719 2.007 3.667 3.457 1.523 1.022 1.463 1.747 2.032
2024/202558.197 7.306 29.122 5.040 4.491 2.321 2.498 3.731 305 643 1.622 494 624
2025/202614.552 1.015 933 1.898 1.238 1.113 1.207 2.685 723 1.127 1.392 922 299
Totale 242.149